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Background 
Losartan is an angiotensin II receptor type 1 (AT1) antagonist. Losartan reduces circulating 
TGFb concentrations in a variety of myopathic models.  We hypothesised that losartan 
administration to the murine osteogenesis imperfecta model OIM would result in lower 
circulating TGFb and CTX (bone resorption marker) and increase bone mass. 
 
Methods 
All procedures were approved by the UConn Health Institutional Animal Care and Use 
Committee and performed in an AAALACi accredited facility. OIM mice were obtained from 
Jackson Labs (Bar Harbor, ME) on a mixed background (B6C3Fe a/a-Col1a2oim/J) for Study 
1 and then rederived onto a pure C57BL6 background for Study 2. 
In study 1 OIM mice were exposed to 0g/l, 0.6g/l and 1.2g/l in drinking water. At sacrifice, 
blood was taken to measure TGFb and CTX. In Study 2, OIM mice were exposed to either 
0g/l or 0.6g/l losartan for 8 weeks; blood and vertebral bodies were taken at sacrifice. 
 
Results 
In Study 1, 4 weeks’ losartan at 0.6g/l, but not 1.2g/l, was associated with a significant 
reduction in TGFb (ng/ml): losartan 0g/l, 79.2 (14.6); 0.6g/l, 60.0 (18.6) p=0.0440 vs 0g/l; 
1.2g/l, 82.1 (18.7); and in CTX (ng/ml): Losartan 0g/l, 275.9 (100.2); 0.6g/l, 157.2 (128.2) 
p=0.0205 vs 0g/l; 1.2g/l, 263.1 (80.7). 
In Study 2, 8 weeks’ losartan treatment at 0.6g/l vs 0g/l was associated with significant 
differences in L3 vertebral body BV/TV%; 63.7 (40.0) vs 10.0 (2.0) p=0.0215; Tb. N. 0.019 
(0.003) vs 0.014 (0.003) p = 0.0158; Tb. Sp. 17.6 (17.4) vs 46.4 (5.3) p=0.0085; and Tb. Th 
33.1 (20.8) vs 6.9 (0.2) p=0.0278. CTX and TGFb measured at 8 weeks were not 
significantly different between treated and control mice. 
 
Discussion 
Losartan 0.6g/l reduced bone turnover and TGFb at 4 weeks and increased vertebral 
trabecular bone mass at 8 weeks. The lack of difference in CTX and TGFb at 8 weeks 
suggests earlier reductions in bone turnover, resulting in increased retention of trabecular 
bone, are carried through to 8 weeks of age when turnover is intrinsically lower in both 
treated and untreated animals.  Further studies are needed to clarify the biological 
mechanisms and pathways involved. 
 
 
 
